Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code
Purpose: Melanoma at the choroid region is the most common primary cancer that affects the eye in adult patients. Concave ophthalmic applicators with 106Ru/106Rh beta sources are the more used for treatment of these eye lesions, mainly lesions with small and medium dimensions. The available treatment planning system for 106Ru applicators is based on dose distributions on a homogeneous water sphere eye model, resulting in a lack of data in the literature of dose distributions in the eye radiosensitive structures, information that may be crucial to improve the treatment planning process, aiming the maintenance of visual acuity.
Methods: The Monte Carlo code MCNPX was used to calculate the dose distribution in a complete mathematical model of the human eye containing a choroid melanoma; considering the eye actual dimensions and its various component structures, due to an ophthalmic brachytherapy treatment, using 106Ru/106Rh beta-ray sources. Two possibilities were analyzed; a simple water eye and a heterogeneous eye considering all its structures. Two concave applicators, CCA and CCB manufactured by BEBIG and a complete mathematical model of the human eye were modeled using the MCNPX code.
Results and Conclusion: For both eye models, namely water model and heterogeneous model, mean dose values simulated for the same eye regions are, in general, very similar, excepting for regions very distant from the applicator, where mean dose values are very low, uncertainties are higher and relative differences may reach 20.4%. For the tumor base and the eye structures closest to the applicator, such as sclera, choroid and retina, the maximum difference observed was 4%, presenting the heterogeneous model higher mean dose values. For the other eye regions, the higher doses were obtained when the homogeneous water eye model is taken into consideration. Mean dose distributions determined for the homogeneous water eye model are similar to those obtained for the heterogeneous eye model, indicating that the homogeneous water eye model is a reasonable one. The determined isodose curves give a good visualization of dose distributions inside the eye structures, pointing out their most exposed volume.
Cite this article as:
Barbosa NA, da Rosa LAR, de Menezes AF, Reis JP, Facure A, Braz D. Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code. Int J Cancer Ther Oncol 2014; 2(3):02038. DOI: 10.14319/ijcto.0203.8
ICRU 72. Dosimetry of beta rays and low-energy photons for brachytherapy with sealed sources. J ICRU 2004; 4:5-8.
Schueler AO, Flühs D, Anastassiou G, et al. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. Int J Radiat Oncol Biol Phys 2006; 65: 1212-21.
Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2000; 238: 129-37.
Lommatzsch PK. ß-irradiation of choroidal melanoma with 106Ru/106Rh- Applicators.16 years' experience. Arch Ophthalmol 1983; 101: 713-7.
Tjho-Heslinga RE, Kakebeeke-Kemme HM, Davelaar J, et al. Results of ruthenium irradiation of Uveal melanoma. Radiotherapy Oncol 1993; 29: 33–8.
Verschueren KM, Creutzberg CL, Schalij-Delfos NE, et al. Long-term outcomes of eye-conserving treatment with Ruthenium (106) brachytherapy for choroidal melanoma. Radiother Oncol 2010; 95: 332–8.
Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A metaanalysis of studies including 1,066 patients. Acta Ophthalmol Scand 1999; 77: 414-7.
Damato B, Patel I, Campbell IR, et al. Visual acuity after Ruthenium (106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys 2005; 63: 392-400.
Kirwan JF, Constable PH, Murdoch IE, Khaw PT. Beta irradiation: new uses for an old treatment: a review. Eye 2003; 17: 207-15.
Nag S, Quivey JM, Earle JD, et al. The American Brachytherapy Society Recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003; 56: 544–55.
Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110: 956-61.
Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam Radiation therapy for the treatment of choroidal melanoma. Ophthalmology 1999; 106: 1579-87.
Koch N, Newhauser WD, Titt U, et al. Monte Carlo calculations and measurements of Absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy. Phys Med Biol 2008; 53: 1581–94.
Moore RF. Choroidal sarcoma treated by intraocular insertion of radon seeds. Br J Ophthalmol 1930; 14: 145–52.
Eckert & Ziegler BEBIG GmbH, User manual Ru-106 eye applicators TD04_002 / Rev. 11/09 2013.
COMS. Collaborative Ocular Melanoma Study Group. Manual of Procedures. Accessed from www.jhu.edu/wctb/coms/
Freire JE, De Potter P, Brady LW, Longton WA. Brachytherapy in primary ocular tumors. Semin Surg Oncol 1997; 13: 167-76.
Finger PT, Lu D, Buffa A, et al. Palladium-103 versus Iodine-125 for ophthalmologic plaque radiotherapy. Int J Rad Oncol Biol Phys 1993; 27: 849-54.
Thomson RM, Rogers DW. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models. Med Phys 2010; 37: 368-76.
Chiu-Tsao ST, Astrahan MA, Finger PT, et al. Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS. Med Phys 2012; 39: 6161-84.
Barbosa NA, da Rosa LAR, Facure A, Braz D. Brachytherapy treatment simulation of strontium-90 and ruthenium-106 plaques on small size posterior uveal melanoma using MCNPX code. Radiation Physics and Chemistry 2014; 95: 224–6.
Astrahan MA. A patch source model for treatment planning of ruthenium ophthalmic applicators. Medical Physics 2003; 30: 1219 –28.
Soares CG, Vynckier S, Järvinen H, et al. Dosimetry of beta-ray ophthalmic applicators: Comparison of different measurement methods. Med Phys 2001; 28: 1373–84.
Rivard MJ, Melhus CS, Sioshansi S, Morr J. The impact of prescription depth, dose rate, plaque size, and source loading on the central-axis using 103Pd, 125I, and 131 Cs. Brachytherapy 2008; 7: 327–35.
Gleckler M, Valentine JD, Silberstein EB. Calculating lens dose and surface dose rates from 90Sr ophthalmic applicators using Monte Carlo modeling. Med Phys 1998; 25:29–36.
Zhang H, Martin D, Chiu-Tsao ST, et al. A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant. Brachytherapy 2010; 9: 362 –72.
Cross WG, Hokkanen J, Järvinen H, et al. Calculation of beta-ray dose distributions from ophthalmic applicators and comparison with measurements in a model eye. Med Phys 2001; 28: 1385–96.
Chiu-Tsao S, O’Brien K, Sanna R, et al. Monte Carlo dosimetry for 125I and 60Co in eye plaque therapy. Med Phys 1986; 13: 678–82.
Fuss MC, Muñoz A, Oller JC, et al. Energy de¬position by a 106Ru/106Rh eye applicator simulat¬ed using LEPTS, a low-energy particle track simula¬tion. Appl Radiat Isot 2011; 69:1198–204.
Pelowitz DB. MCNPXTM User’s Manual Version 2.5.0. Los Alamos National Laboratory report LA-CP-05-0369. 2005.
Briesmeister J F. A General Monte Carlo code for neutron and photon transport, Version 3A. Los Alamos, NM, Los Alamos National Laboratory, LA-12625-M.March. 1997.
Davelaar J, Schaling DF, Hennen LA, Broerse JJ. Dosimetry of ruthenium-106 eye applicators. Med Phys 1992; 19: 691–4.
Brualla L, Sempau J, Sauerwein W. Comment on Monte Carlo calculation of the dose distributions of two 106Ru eye applicators [Radiother Oncol 1998: 49; 191-196]. Radiother Oncol 2012; 104: 267–8.
Chan MF, Fung AY, Hu YC, et al. The measurement of three dimensional dose distribution of a ruthenium-106 ophthalmological applicator using magnetic resonance imaging of BANG polymer gels. J Appl Clin Med Phys 2001; 2: 85–9.
ICRP PUBLICATION 89. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Editor J. VALENTIN. International Commission on Radiological Protection. 2003.
ICRU 46. Photon, Electron, Photon and Neutron Interaction Data for Body Tissues. DC Washington 1992.
Hermida-López M. Calculation of dose distributions for 12 106Ru/106Rh ophthalmic applicator models with the PENELOPE Monte Carlo code. Med Phys 2013; 40: 101705.
Marconi DG, Castro DG, Rebouças LM, et al. Tumor control, eye preservation and visual outcomes of ruthenium plaque brachytherapy for choroidal melanoma. Brachytherapy 2013; 12: 235-9.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.